G7 Dual Mobility With Vivacit-E or Longevity PMCF
← catalyst calendarNCT05548972 · readout ≤ 3,818 d
Sponsored by Zimmer Biomet (industry) · ZBH — their whole pipeline →.
Phase
Not applicable
Status
Enrolling by invitation
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
358estimated
Sites
10
Countries
Belgium, Italy, South Korea +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-03-20 | actual | When the study began enrolling |
| Primary completion | Jan 2037 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2037 | estimated | The whole study's end, after follow-up |
| First posted | 2022-09-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-06-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Hip Osteoarthritis
- Rheumatoid Arthritis
- Joint Diseases
- Avascular Necrosis
- Dislocation, Hip
- Femoral Neck Fractures
- Trochanteric Fractures
- Revision Surgeries
Interventions
- Device: G7 Dual Mobility with Vivacit-E bearing
- Device: G7 Dual Mobility Longevity bearing
Primary outcomes
what the primary-completion date above is the date OFSurvival of the implant system
measured 10 years
Safety of the implant system
measured 10 years
Permalink · ZBH's whole pipeline · Catalyst calendar · Every registered study · What changed